Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Clin Invest ; 124(1): 328-37, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24292712

RESUMEN

Multiple intestinal atresia (MIA) is a rare cause of bowel obstruction that is sometimes associated with a combined immunodeficiency (CID), leading to increased susceptibility to infections. The factors underlying this rare disease are poorly understood. We characterized the immunological and intestinal features of 6 unrelated MIA-CID patients. All patients displayed a profound, generalized lymphocytopenia, with few lymphocytes present in the lymph nodes. The thymus was hypoplastic and exhibited an abnormal distribution of epithelial cells. Patients also had profound disruption of the epithelial barrier along the entire gastrointestinal tract. Using linkage analysis and whole-exome sequencing, we identified 10 mutations in tetratricopeptide repeat domain­7A (TTC7A), all of which potentially abrogate TTC7A expression. Intestinal organoid cultures from patient biopsies displayed an inversion of apicobasal polarity of the epithelial cells that was normalized by pharmacological inhibition of Rho kinase. Our data indicate that TTC7A deficiency results in increased Rho kinase activity, which disrupts polarity, growth, and differentiation of intestinal epithelial cells, and which impairs immune cell homeostasis, thereby promoting MIA-CID development.


Asunto(s)
Atresia Intestinal/genética , Mucosa Intestinal/patología , Proteínas/genética , Inmunodeficiencia Combinada Grave/genética , Secuencia de Bases , Polaridad Celular , Células Cultivadas , Niño , Consanguinidad , Análisis Mutacional de ADN , Células Epiteliales/fisiología , Exoma , Femenino , Estudios de Asociación Genética , Ligamiento Genético , Humanos , Lactante , Atresia Intestinal/inmunología , Atresia Intestinal/mortalidad , Atresia Intestinal/patología , Ganglios Linfáticos/patología , Linfopenia/genética , Linfopenia/inmunología , Linfopenia/patología , Masculino , Linaje , Proteínas/metabolismo , Inmunodeficiencia Combinada Grave/inmunología , Inmunodeficiencia Combinada Grave/mortalidad , Inmunodeficiencia Combinada Grave/patología , Timo/anomalías , Timo/patología , Quinasas Asociadas a rho/metabolismo
2.
Eur J Paediatr Neurol ; 16(5): 542-8, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22342071

RESUMEN

AIMS: Description of the clinical course in a child compound heterozygous for POLG1 mutations, neuropathology findings and results of dietary treatment based on fasting avoidance and long chain triglycerides (LCT) restriction. RESULTS: At 3(1/2) months of age the patient presented with severe hypoglycemia, hyperlactatemia, moderate ketosis and hepatic failure. Fasting hypoglycemia occurred 8 h after meals. The hypoglycemia did not respond to glucagon. She was supplemented with IV glucose and/or frequent feedings, but developed liver insufficiency which was reversed by long-chain triglyceride (LCT) restriction. Alpha-foeto-protein (AFP) levels were elevated and returned to low values after dietary treatment. Liver biopsy displayed cirrhosis, bile ductular proliferation, steatosis, isolated complex IV defect in part of the liver mitochondria, and mitochondrial DNA depletion (27% of control values). Two heterozygous mutations (p. [Ala467Thr] + p. [Gly848Ser]) were found in the POLG1 gene. At 3 years of age she progressively developed refractory mixed type seizures including a focal component and psychomotor regression which fulfilled the criteria of Alpers syndrome (AS) although the initial presentation was compatible with infantile myocerebrohepatopathy spectrum (MCHS). She died at 5 years of age of respiratory insufficiency. Neuropathologic investigation revealed lesions in the right striatal area and the inferior colliculi typical for Leigh's encephalopathy. CONCLUSION: The present patient showed an evolution from infantile MCHS to AS, and dietary treatment seemed to slow the progression of liver failure. In spite of the late clinical features of AS, it extends the neuropathological spectrum of AS and polymerase gamma deficiency (POLG) to Leigh syndrome lesions.


Asunto(s)
Encéfalo/patología , ADN Polimerasa Dirigida por ADN/deficiencia , Esclerosis Cerebral Difusa de Schilder/genética , Enfermedad de Leigh/genética , Fallo Hepático/genética , Preescolar , ADN Polimerasa gamma , ADN Mitocondrial/genética , Esclerosis Cerebral Difusa de Schilder/patología , Progresión de la Enfermedad , Resultado Fatal , Femenino , Encefalopatía Hepática/genética , Encefalopatía Hepática/patología , Humanos , Lactante , Enfermedad de Leigh/patología , Fallo Hepático/patología , Mutación
3.
J Inherit Metab Dis ; 33 Suppl 3: S139-43, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20151198

RESUMEN

Deficiency of the cytosolic enzyme thymidine phosphorylase (TP) causes a multisystem disorder called mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) syndrome. Clinical symptoms are gastrointestinal dysfunction, muscle involvement and neurological deterioration. TP deficiency is biochemically characterised by accumulation of thymidine and deoxyuridine in body fluids and compromised mitochondrial deoxyribose nucleic acid (mtDNA) integrity (depletion and multiple deletions). In this report we describe a patient with the clinical and biochemical features related to the end stage of the disease. Home parenteral nutrition had started to improve the clinical condition and preparations were initiated for stem cell transplantation (SCT) as a last resort treatment. Unfortunately, the patient died during the induction phase of SCT. This report shows that TP deficiency is a severe clinical condition with a broad spectrum of affected tissues. TP deficiency can be easily determined by the measurement of pyrimidine metabolites in body fluids and TP activity in peripheral blood leucocytes. Early detection and treatment may prevent the progress of the clinical symptoms and, therefore, should be considered for inclusion in newborn screening programmes.


Asunto(s)
Seudoobstrucción Intestinal/enzimología , Encefalomiopatías Mitocondriales/enzimología , Timidina Fosforilasa/deficiencia , Adolescente , Adulto , Biomarcadores/análisis , Análisis Mutacional de ADN , Progresión de la Enfermedad , Resultado Fatal , Femenino , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Humanos , Seudoobstrucción Intestinal/diagnóstico , Seudoobstrucción Intestinal/genética , Seudoobstrucción Intestinal/terapia , Masculino , Encefalomiopatías Mitocondriales/diagnóstico , Encefalomiopatías Mitocondriales/genética , Encefalomiopatías Mitocondriales/terapia , Distrofia Muscular Oculofaríngea , Oftalmoplejía/congénito , Nutrición Parenteral en el Domicilio , Linaje , Fenotipo , Pronóstico , Índice de Severidad de la Enfermedad , Trasplante de Células Madre , Timidina Fosforilasa/genética , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA